1) NO release in vitro
NO体外释放
2) drug release in vitro
体外释放
1.
Programming model methodology for data of drug release in vitro;
体外释放拟合模板编程及应用实例
2.
OBJECTIVE To prepare thymopentin microspheres and investigate the drug release in vitro.
目的制备胸腺五肽微球并对其体外释放进行考察。
3.
Several characteristics of c hitosan nanoparticles such as morphology,particle size,zeta potential,drug entra pment efficiency and drug release in vitro were evaluated.
方法 采用酶水解和超滤膜分离技术 ,得到不同相对分子质量的壳聚糖 ,由凝胶渗透色谱法测定其相对分子质量 ;采用溶剂扩散法制备纳米粒 ,研究纳米粒的空间结构 ,测定其粒径、表面电位 (zeta电位 )、模型药物胰岛素包封率及体外释放。
3) in vitro dissolution
体外释放
1.
Preparation and in vitro dissolution of the solid dispersions of cinnamon oil;
肉桂油固体分散体的制备及体外释放
2.
Preparation and in vitro dissolution of glipizide sustained-release pellet capsules;
格列吡嗪缓释微丸胶囊的制备及其体外释放
3.
Preparation and in vitro dissolution of diclofenac sodium sustained-release tablets;
双氯芬酸钠缓释片的制备和体外释放度研究
4) release in vitro
体外释放
1.
Preparation of diclofenac sodium liposomes by active loading method and its release in vitro;
主动载药法制备双氯芬酸钠脂质体及其体外释放
2.
Influence of gel vehicles on release in vitro and transdermal resorption of integerrimine;
不同基质对全缘千里光碱凝胶剂体外释放和透皮特性的影响
3.
Preparation of irinotecan hydrochloride containing liposomes by ammonium sulfate gradient method and its release in vitro
硫酸铵梯度法制备盐酸伊立替康脂质体及体外释放的研究
5) in vitro release
体外释放
1.
Study on preparation and in vitro release characteristics of Bitongning Patch;
痹痛宁贴剂的制备及体外释放、透皮吸收研究
2.
Preparation and in vitro release of Niacin sustained-release tablets;
烟酸缓释骨架片的制备及体外释放度考察
3.
A study on the preparation and in vitro release models of doxorubicin-nanoparticles;
阿霉素纳米粒的制备与模拟体外释放行为
6) in vitro drug release
体外释放
1.
A mathematic model was proposed based on the experimental results and theoretical analysis of in vitro drug release.
为研究和改进基质中药物的体外释放特性 ,以雌二醇为模型药物 ,制备了具有储库层的复合基质型经皮给药控释系统 ,进行了体外释放实验 ,测定了释放曲线 ,建立了复合基质型药物控释系统在体外分层释放的数学模型。
2.
OBJECTIVE To prepare praziquantel implants and investigate the in vitro drug release.
目的制备吡喹酮(PZQ)植入剂并对其体外释放进行考察。
补充资料:[3-(aminosulfonyl)-4-chloro-N-(2.3-dihydro-2-methyl-1H-indol-1-yl)benzamide]
分子式:C16H16ClN3O3S
分子量:365.5
CAS号:26807-65-8
性质:暂无
制备方法:暂无
用途:用于轻、中度原发性高血压。
分子量:365.5
CAS号:26807-65-8
性质:暂无
制备方法:暂无
用途:用于轻、中度原发性高血压。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条